All News

Ending the subsidies offered under the Affordable Care Act would sharply increase costs for consumers, according to a study from the RAND Corporation. Furthermore, without the subsidies, more than 11 million Americans will lose their health insurance.

An article in the Journal of the American Medical Association outlines what both CMS and the Pioneer ACOs have learned in the early years of the program, such as the importance of engaging primary care physicians, not growing too quickly, and the need to find better ways to count which patients are in the ACO.

The study, published in JAMA, evaluates the impact of the a decrease in single-physician practices as doctors prefer to join larger healthcare organizations.

The CDC has released guidelines with detailed information on the type of personal protective equipment and the procedure for donning and removing, for healthcare workers managing Ebola patients.

The Institute of Medicine announced yesterday that A. Mark Fendrick, MD, co-editor-in-chief of The American Journal of Managed Care and a national leader in efforts to reform healthcare reimbursement strategies, is among 70 new members elected to the prestigious body.

WhyNotTheBest.org maintained by The Commonwealth Fund is a free resource for healthcare professionals interested in tracking performance on various measures of healthcare quality.

Congressional candidates may be still be talking about the Affordable Care Act, but a majority of the uninsured are still unaware of main components of the law, according to a poll from the Kaiser Family Foundation.

Taiho Oncology, Inc, announced that the FDA granted Fast Track designation for an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer.

The paper, published in Nature, has identified a "switch" that can be inhibited to restrict tumor growth.

The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.

Industry experts discussed the big issues facing accountable care organizations (ACO) at the Brookings Institute's event, The State of Accountable Care: Evidence to Date and Next Steps, held Monday in Washington, DC.

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

As accountable care organizations, or ACOs, proliferate across the United States, a question arises for both veteran healthcare leaders and consumers: is the ACO something new, or just a relabeling of managed care vehicles created during the last wave of healthcare reform? A well-run ACO offers something better than the managed care of prior years, according to presenters at the gathering of the ACO and Emerging Healthcare Coalition, which took place October 16-17, 2014, in Miami, Florida.

Providers and insurers across the country are partnering to launch narrow-network plans even as controversy continues over whether these plans offer adequate provider access for consumers.

Attendees at the ACO and Emerging Healthcare Delivery Coalition meeting held October 16-17, 2014, in Miami, Fla., gained insights to help physicians and accountable care organizations achieve the "Triple Aim" of better population health, greater patient satisfaction, and lower costs. This initiative of The American Journal of Managed Care has now attracted more than 120 members.

The Office of the National Coordinator for Health Information Technology unveiled a draft for its 10-year plan for healthcare interoperability at a joint meeting on October 15.

A study presented at ASCO's Quality Care Symposium in Boston found increased medication adherence to prevent breast cancer recurrence in those availing of the subsidies.

A new initiative from the Robert Wood Johnson Foundation will explore how health information and data can be used to improve health in the community.

The Decipher test is intended for use in men who have undergone radical prostatectomy and are at a high risk of disease recurrence.

Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.

The non-invasive nature of the test makes it a very attractive alternative to the uncomfortable colonoscopy used to detect colorectal cancer. In a New England Journal of Medicine study of 10,000 patients, the test identified 92% of colorectal cancers in average-risk patients and 42% of polyps.

Brincidofovir is being developed by the company against several different viruses, including smallpox and Ebola.